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Abstract Sixty-three natalizumab-treated patients with re-
lapsing multiple sclerosis were screened for JC polyomavirus
(JCV) viruria. Urinary-positive patients were longitudinally
sampled for up to 24 weeks. Using methods that distinguish
encapsidated virus from naked viral DNA, 17.5 % of patients
were found to excrete virus, consistent with the prevalence of
urinary excretion in the general population. Unexpectedly,
urinary excretion was predominantly seen (>73 %) in patients
with high JC antibody index (≥2.0). Active JCV infection,
therefore, tends to occur in natalizumab patients that carry a
high risk factor for the development of disease, directly
linking JC infection to the risk factors for PML development.
Keywords ProgressiveMultifocal Leukoencephalopathy
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Introduction
Natalizumab is a highly efficacious therapy for patients with
relapsing multiple sclerosis (MS) but is associated with induc-
tion of Progressive Multifocal Leukoencephalopathy (PML),
a debilitating or fatal brain infection of the JC polyomavirus
(JCV) (Wollebo et al. 2015). The risk for development of
PML is correlated with a patient’s prior exposure to the virus
(Rudick et al. 2010; Bloomgren et al. 2012) quantified from
anti-JCVantibodies and expressed as the antibody index (AI)
(Plavina et al. 2014). Ninety-six percent of PML cases in
controlled studies arose in patients with AI>0.9, and 84 %
of cases arose in patients with AI>1.5 (Plavina et al. 2014).
Utilization of the anti-JCV antibody titer/index in treatment
algorithms would therefore be expected to result in a reduced
rate of PML. However, in the nearly 4 years since antibody
titer or AI has been used as a means of risk stratification, there
has been only a modest reduction in the incidence of PML
arising from natalizumab treatment (Fig. 1) (Biogen Idec and
Biogen Natalizumab Safety Updates March 4, 2011 through
September 4, 2015; www.biogen.com).
A possible deficiency in the AI risk stratification approach
is its dissociation from JCV infection itself. Indeed, antibodies
are merely markers of the history of immune responses to
JCV-specific antigen exposure, which could reflect prior ex-
posure to virus from weeks to many years in the past.
Assessment of concurrent viral infection might be more accu-
rate in determining the real-time viral status in patients. The
accessible compartment in living patients from which JC viral
load can be routinely measured is the genitourinary compart-
ment and the bonemarrow (Ryschkewitsch et al. 2004).While
the pathogenic form of JC virus in the CNS may originate
from virus in the genitourinary compartment, the genomic
rearrangements associated with the brain-infective form are
rarely seen in urine (Van Loy et al. 2013) and it is often re-
ported that urinary excretion of JCV is intermittent (Lanzillo
et al. 2014; Delbue et al. 2015; Domínguez-Mozo et al. 2013;
Berger et al. 2013). We interrogated the urine of 63
natalizumab-treated patients to evaluate whether viruria was
intermittent, whether virus, or only viral DNA, was found and
to evaluate the relationship between urinary virus and known
risk factors for progression to PML. We found that MS pa-
tients treated with natalizumab who excreted JC virus did so
consistently, that the bulk of the viral DNA signal is likely to
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derive from encapsidated virus and that the majority of pa-
tients with persistent excretion are just those patients with high
AI. Thus, the majority of patients in the high-risk category for
progression to PML also have an active JCV infection.
Patients and methods
The study was approved by an institutional review board
(Quorum IRB, Seattle, WA), and informed consent was ob-
tained for each patient by his/her treating physician prior to
providing medical information or screening sample. Study
participants were natalizumab-treated MS patients at least
6 months on therapy and screened for the presence or absence
of JCV viruria. Patients with a positive screening test were
given 24 weekly urine collection kits, and first-morning sam-
ples were collected 7±2 days apart. AI, gender, number of
natalizumab-infusions, and prior or concurrent treatments for
MS or other co-morbid indications were recorded. Weekly
urine samples were self-collected and shipped at ambient tem-
perature to Inhibikase Therapeutics (Atlanta, GA and
Cambridge, MA).
Sample processing was performed to discriminate virus-
associated viral DNA from all other forms in the sample.
For total viral DNA, 1 mL unfiltered, uncentrifuged urine
was heated to 60 °C for 10 min in 2 mM dithiothreitol
(DTT), 50 mM Na2EDTA, and 50 mM K2EGTA. These con-
ditions disrupt encapsidated virus in phosphate-buffered sa-
line (Neu et al. 2010). For virus-associated viral DNA, 1 mL
unfiltered, uncentrifuged urine was treated with 25 u/mL
Benzonase® (EMD Millipore), a DNA exo-/endonuclease,
for 10 min at 37 °C, followed by heat/DTT/EDTA/EGTA
treatment as for processing of total viral DNA. Cell-
associated viral DNA that was not encapsidated was deter-
mined to be absent or making a minimal contribution to the
observed qPCR signal in these samples since the viral DNA in
urine resisted Benzonase® treatment even following overnight
incubation in 25 % (v/v) non-protein-denaturing detergents
(e.g., M-Per, ThermoFisher), a condition wherein
Benzonase® remained active. Total viral DNA and virus-
essed samples each week by quantitative polymerase chain
reaction (qPCR) at a reference laboratory, Viracor IBT.
Viracor’s proprietary PCR protocol primes within a highly
conserved region of the large T-antigen using proprietary
primer sequences closely related to previously published
methods (Ryschkewitsch et al. 2004). Viracor’s limit of quan-
titation (LOQ), defined as a day-to-day qPCR variation of
≤30 %, is 151 genome equivalents/mL urine (Geq/mL). The
qPCR amplification protocol is proprietary to Viracor IBT, but
fails to amplify non-target DNA samples, even from other
human polyomaviruses like BK, in validation experiments.
Details of the amplification and validation criteria may be
requested directly from Viracor IBT. Any sample measuring
below 151 was recorded as having a signal <151 and could be
distinguished from samples that had no signal at all.
Results
Sixty-three natalizumab-treated patients were screened for the




















Safety update reporting date 
Fig. 1 Rate of PML case
occurrence and incidence during
the era of JCVantibody testing in
natalizumab-treated patients.
Each point represents the overall
incidence rate per 1000
natalizumab-treated patients at
each safety update, computed
from the total number PML cases
and the reported total exposure to
natalizumab in the post-market
setting. There has been a modest
reduction in incidence rate in the
last 24 months. The approval, in
January, 2012, for JC antibody
titer/index test is indicated with
the arrow
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associated viral DNA were measured from duplicate proc-
(17.5 %) and provided up to 24 weekly urine samples proc-
essed as described. Longitudinal sampling revealed that uri-
nary viral load varied between 2.2 and 7.8 log10 Geq/mL
(Table 1) among the screen-positive patients, but within a
patient, viral load measured consistently (Table 1). Only one
patient, 9027, displayed intermittent excretion, with virus-
associated viral DNA found in 18 of 24 samples and close
to the LOQ (Table 1). Three screen-negative patients with
AI of 1.8, 1.5, or 1.35 also provided 24 weekly samples.
Two of these screen-negative patients had a total viral DNA
signal in 1 of 24 samples; the third patient displayed a total
viral DNA signal in 2 of 24 samples. However, the total viral
DNA signal degraded following Benzonase® treatment, indi-
cating that these samples did not contain encapsidated virus.
Thus, with one sample’s exception out of 72 collected, screen-
negative patients remained negative throughout the study
period.
Urine processing is likely reducing the viral DNA signal in
patient samples to just the virus-associated viral DNA,
allowing for a direct measure of patient viral load shed from
the genitourinary compartment. Correlates were sought be-
tween urinary viral load and PML risk factors. Three of 52
patients with AI<2.0 were viruric (5.8 %), in contrast to the
72.7 % of patients with AI≥2.0 that consistently excreted
virus (Fig. 2). Since 84 % of PML cases in controlled studies
arose in patients with AI>1.5, the majority of patients with
active JC infection detected in the urine were just those
patients considered to be in the high-risk category for
progression to PML (Plavina et al. 2014; McGuigan et al.
2015).
Discussion
Among the three established risk factors for progression to
PML during natalizumab treatment (AI, treatment duration,
prior immunosuppressant use) (Plavina et al. 2014;
McGuigan et al. 2015), AI has been used to determine which
patients should initiate natalizumab therapy and at what point
a patient should be transitioned to alternatives. Given that
PML cases have continued to increase with only a modest
reduction since antibody titer/AI measurements were intro-
duced (Fig. 1) (www.biogen.com), augmenting risk
algorithms with additional risk factors seems imperative.
The prevalence of JCV viruria among natalizumab-treated
patients is reported to cover a wide range (18–87 %)
(Delbue et al. 2015; Lanzillo et al. 2014; Laroni et al. 2012;
Bellizzi et al. 2013; Rinaldi et al. 2010), but no association
between viruria prevalence and progression to PML has been
found. The strong correlation demonstrated herein betweenAI
and JCV viruria indicates that natalizumab-treated patients
with active JCV infection commonly fall into a high-risk cat-
egory for progression to clinical disease (Plavina et al. 2014).
Ferrante and co-workers made a similar observation, finding
that more than 80 % of patients with viruria were also sero-
positive for JCV-specific antibodies, but could not assign
these observations to low or high PML risk groups since the
AI had not yet been introduced into clinical practice (Delbue
et al. 2015). For this reason, measurement of urinary excretion
has not accompanied analysis of AI in PML cases either. It had
been previously concluded that viruria is not correlated with
serostatus or antibody titer in PML cases (Rudick et al. 2010)
Table 1 Longitudinal sampling










8002 0.65 18 5.51 ± 0.45 (24) 5.16 ± 0.61 (24)
9027 0.98 19 3.13 ± 0.44 (24) 3.27 ± 0.5 (24)
8010 1.7 22 5.98 ± 0.41 (24) 6.00 ± 0.55 (24)
8006 2.0 8 7.03 ± 0.44 (24) 6.93 ± 0.66 (24)
9040 2.1 12 4.08 ± 0.61 (24) 4.01 ± 0.76 (24)
8013 2.4 51 7.83 ± 0.19 (24) 7.84 ± 0.20 (24)
8001 2.8 38 5.91 ± 0.46 (24) 5.80 ± 0.53 (24)
8005 2.6 51 4.02 ± 0.68 (24) 3.97 ± 0.53 (24)
9033 3.1 13 6.22 ± 0.58 (24) 6.12 ± 0.58 (24)
9028 3.3 6 6.91 ± 0.46 (24) 6.71 ± 0.81 (24)
8003 3.8 101 6.80 ± 0.59 (24) 6.77 ± 0.62 (24)
Total or virus-associated viral DNA is defined in BPatients and methods^. AI shown was that last measured prior
to the screening sample having been collected. The number of infusions represents the total number of
natalizumab infusions prior to the screening sample
a The number of weeks of collection completed is indicated in parentheses
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and not even the prevalence of JCV excretion in PML cases
has been systematically measured. The clear correlation be-
tween AI and viruria reported herein should force re-
examination of this issue in PML cases.
The introduction of new handling procedures for patient
urine has resulted in consistent measurement of patient viral
loads for genitourinary virus. These methods may overcome
the reported observation that JCV viruria is intermittent (see
Clausi et al. 2015; Delbue et al. 2015; Lanzillo et al. 2014;
Domínguez-Mozo et al. 2013; Saundh et al. 2010 for exam-
ples). The introduction of DNAse and chemical treatments
suggests that actual, encapsidated virus can now be quantified
in patient samples. Intermittent excretion made the measure of
urinary JCV of little diagnostic benefit, leaving it largely ig-
nored in the approach to mitigating PML risk. Given that
appropriate interrogation of the urine reveals a consistent sig-
nal that likely represents encapsidated virus, that the viral load
is high and strongly correlated with high antibody titer, and
the fact that the level of viruria increases with progression to
PML (Delbue et al. 2015; Bellizzi et al. 2013; Domínguez-
Mozo et al. 2015) suggest urinary JCV has clinical value.
Active JCV infection in the urine can often be detected prior
to JCV antibodies (Laroni et al. 2012; Lanzillo et al. 2014),
directing attention to those patients that may already be head-
ing down the path to neurotropic JCV. The conundrum has
always been where the transformation from genitourinary
(i.e., archetype) to neurotropic JCV takes place. Correlation
between the site(s) of viral replication, the prevalence of viral
excretion, the level of viral replication, and the antibody titer/
index, as described herein, may point the finger at the primary
JCV reservoir as the site of origin for neurotropic JCV, but
whose independence from the reservoir is established after
initial escape (Reid et al. 2011; Van Loy et al. 2015).
Consistent with this hypothesis, genomic rearrangements
and VP1 capsid mutations, both implicated in enabling virus
to migrate into other tissues and organs, have only been iden-
tified from plasma or serum, PBMC subsets, and PML brain
or cerebrospinal fluid (CSF) (Reid et al. 2011; Gorelik et al.
2011). PML remains rare, a consequence of the rarity of
events necessary to enable JCV mobilization and migration
during natalizumab treatment. The selective pressure to mu-
tate will increase for the virus once it leaves its traditional
replicative milieu, driving the types of transformations that
have now been documented in both coding and non-coding
regions of the viral genome. But therapeutic intervention may
best be focused at the origin of these events and along the path
leading to the CNS. With the ability to directly measure pa-
tient viral load from an accessible compartment now
established, a biomarker exists from which the response to
antiviral therapy can begin to be measured in natalizumab
patients.
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